These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23277506)

  • 21. Patterns of adverse drug reaction signals in NAFDAC pharmacovigilance activities from January to June 2015: safety of drug use in Nigeria.
    Awodele O; Aliu R; Ali I; Oni Y; Adeyeye CM
    Pharmacol Res Perspect; 2018 Oct; 6(5):e00427. PubMed ID: 30324768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cutaneous adverse drug reactions to psychotropic drugs and their risk factors - a case-control study.
    Greil W; Zhang X; Stassen H; Grohmann R; Bridler R; Hasler G; Toto S; Bleich S; Kasper S
    Eur Neuropsychopharmacol; 2019 Jan; 29(1):111-121. PubMed ID: 30424913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Comparison of Adverse Drug Reaction Profiles in Patients on Antiretroviral and Antitubercular Treatment in Zimbabwe.
    Masuka JT; Chipangura P; Nyambayo PP; Stergachis A; Khoza S
    Clin Drug Investig; 2018 Jan; 38(1):9-17. PubMed ID: 28965312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw LC; Irlam JH; Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Dec; (12):CD004246. PubMed ID: 21154355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Causality assessment in pharmacovigilance: The French method and its successive updates.
    Miremont-Salamé G; Théophile H; Haramburu F; Bégaud B
    Therapie; 2016 Apr; 71(2):179-86. PubMed ID: 27080836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comprehensive intervention for adverse drug reactions identification and reporting in a Pediatric Emergency Department.
    Morales Ríos O; Jasso Gutiérrez L; Talavera JO; Téllez-Rojo MM; Olivar López V; Garduño Espinosa J; Muñoz Hernández O
    Int J Clin Pharm; 2016 Feb; 38(1):80-7. PubMed ID: 26499501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Under-reporting of adverse drug reactions, a problem that also involves medicines subject to additional monitoring. Preliminary data from a single-center experience on novel oral anticoagulants].
    Patrignani A; Palmieri G; Ciampani N; Moretti V; Mariani A; Racca L
    G Ital Cardiol (Rome); 2018 Jan; 19(1):54-61. PubMed ID: 29451510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacovigilance - The next chapter.
    Moore N; Berdaï D; Blin P; Droz C
    Therapie; 2019 Dec; 74(6):557-567. PubMed ID: 31623850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patterns of adverse drug reaction signals in NAFDAC Pharmacovigilance activities from September to November, 2014.
    Awodele O; Ibrahim A; Orhii P
    Int J Risk Saf Med; 2016 Mar; 28(1):13-23. PubMed ID: 27176753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cutaneous drug-reactions to nevirapine: study of risk factors in 101 HIV-infected patients].
    Pitche P; Drobacheff-Thiebaut C; Gavignet B; Mercier M; Laurent R
    Ann Dermatol Venereol; 2005 Dec; 132(12 Pt 1):970-4. PubMed ID: 16446639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does spontaneous adverse drug reactions' reporting differ between different reporters? A study in Toulouse Pharmacovigilance Centre.
    Nicol C; Moulis F; Bondon-Guitton E; Durrieu G; Montastruc JL; Bagheri H
    Therapie; 2019 Oct; 74(5):521-525. PubMed ID: 31029402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequency and Nature of Adverse Drug Reactions Due to Non-Prescription Drugs in Children: A Retrospective Analysis from the French Pharmacovigilance Database.
    Durrieu G; Maupiler M; Rousseau V; Chebane L; Montastruc F; Bondon-Guitton E; Montastruc JL
    Paediatr Drugs; 2018 Feb; 20(1):81-87. PubMed ID: 28766184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted Spontaneous Reporting: Assessing Opportunities to Conduct Routine Pharmacovigilance for Antiretroviral Treatment on an International Scale.
    Rachlis B; Karwa R; Chema C; Pastakia S; Olsson S; Wools-Kaloustian K; Jakait B; Maina M; Yotebieng M; Kumarasamy N; Freeman A; de Rekeneire N; Duda SN; Davies MA; Braitstein P
    Drug Saf; 2016 Oct; 39(10):959-76. PubMed ID: 27282427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of different methods for causality assessment of adverse drug reactions.
    Behera SK; Das S; Xavier AS; Velupula S; Sandhiya S
    Int J Clin Pharm; 2018 Aug; 40(4):903-910. PubMed ID: 30051231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacovigilance for antiretroviral drugs in Africa: lessons from a study in Abidjan, Cote d'Ivoire.
    Jaquet A; Djima MM; Coffie P; Kacou HD; Eholie SP; Messou E; Minga A; Guehi C; Yavo JC; Bissagnene E; Dabis F; Ekouevi DK;
    Pharmacoepidemiol Drug Saf; 2011 Dec; 20(12):1303-10. PubMed ID: 21735508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neonatal adverse drug reactions: an analysis of reports to the French pharmacovigilance database.
    Kaguelidou F; Beau-Salinas F; Jonville-Bera AP; Jacqz-Aigrain E
    Br J Clin Pharmacol; 2016 Oct; 82(4):1058-68. PubMed ID: 27276109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal.
    Herdeiro MT; Ribeiro-Vaz I; Ferreira M; Polónia J; Falcão A; Figueiras A
    Drug Saf; 2012 Aug; 35(8):655-65. PubMed ID: 22788235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trends in culprit drugs and clinical entities in cutaneous adverse drug reactions: a retrospective study.
    Wang F; Zhao YK; Li M; Zhu Z; Zhang X
    Cutan Ocul Toxicol; 2017 Dec; 36(4):370-376. PubMed ID: 28423957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance.
    Fornasier G; Taborelli M; Francescon S; Polesel J; Aliberti M; De Paoli P; Baldo P
    Int J Clin Pharm; 2018 Aug; 40(4):795-802. PubMed ID: 29785683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.